September 28, 2012

Don't rule out IFN/ribavirin for HIV patients with hep C cirrhosis: study

Publish date: Sep 27, 2012

Clinical

Last Updated: 2012-09-27 18:45:28 -0400 (Reuters Health)

By Anne Harding

NEW YORK (Reuters Health) - In HIV patients with hepatitis C, compensated cirrhosis should not be considered a contraindication to therapy with pegylated interferon (peg-IFN) and ribavirin, researchers say.

As is the case in patients without HIV, peg-IFN plus ribavirin is more effective against hep C in HIV patients who are free of cirrhosis, the researchers reported online September 5th in Clinical Infectious Diseases.

"In spite of that, this antiviral combination still leads to an appreciable rate of sustained virological response in cirrhotic patients carrying HCV genotype 3," Dr. Jose A. Mira and Dr. Juan A. Pineda of Hospital Universitario de Valme in Seville, Spain, who helped conduct the new study, told Reuters Health.

While compensated liver cirrhosis is known to predict worse response to IFN plus ribavirin in patients who are only infected with HCV, the researchers note, just one small study has looked at the issue in individuals who are co-infected with HIV. That study, which included 41 patients, found similar rates of sustained viral response (SVR) for patients with and without cirrhosis.

To investigate further, Dr. Mira, Dr. Pineda and their colleagues looked at 629 HIV/HCV co-infected patients receiving treatment with peg-IFN and ribavirin, all of whom had undergone a liver biopsy or liver stiffness measurement within a year of beginning treatment. Twenty-eight percent had cirrhosis.

Intention-to-treat analysis showed SVR in 25% of patients with cirrhosis and 39% of cirrhosis-free patients (p=0.001). Among the patients with cirrhosis, SVR occurred in 14% of those with HCV genotype 1; 47% of patients with HCV genotype 2-3; and 30% of patients with HCV genotype 4.

Part of the difference in response could have been due to the fact that 17% of the cirrhotic patients discontinued treatment due to adverse events, compared to 8% of those without cirrhosis, the researchers note.

"We think that the efficacy of pegylated interferon plus ribavirin in HIV/HCV co-infected patients with HCV genotype 4 depends primarily on other known predictors of response to HCV therapy in these patients, specifically the IL28B genotype," Dr. Mira and Dr. Pineda said via email.

"In fact, in another study carried out in our research group (Mira JA et al. AIDS 2012; 26:1721-1724), we found that only IL28B genotype CC was associated with sustained virological response in this population," they continued. "There are data supporting that interferon-mediated immune response against HCV, which is associated with IL28B genotype, has a different impact depending on HCV genotype. To confirm this hypothesis, a study with a higher number of HCV-4-infected patients would be required."

Despite the fact that patients co-infected with HIV and HCV who have compensated cirrhosis are a "hard-to-cure population," the researchers add, HCV therapy should be a priority in these patients, "given that once decompensated cirrhosis emerges, death due to liver failure occurs in the short-term."

SOURCE: http://bit.ly/PIZa5p

Clin Infect Dis 2012.

Source

September 22, 2012

Companies may be holding back HCV cure

3dacd_web_Margaret_and_Gary_Dudley_at_the_Alamo_Colleges_open_house_earlier_this_week_photo_be_Speedy_Gonzalez_

Hepatitis-C (HCV) is a virus that attacks the liver – it can be deadly and its effects (fatigue, nausea, weight loss, body aches) can be disabling. The disease can also behave like a silent killer, destroying a person’s liver over years without any symptoms. The Centers for Disease Control (CDC) recently issued a warning and recommends that everyone between the ages of 45 and 65 be tested -- potentially millions more could have the virus and not even know it. This story is about a cure for the disease -- a cure patients can’t get access to.

By Angela Covo | 21 de septiembre de 2012

San Antonio.- Hepatitis-C (HCV) is a virus that attacks the liver – it can be deadly and its effects (fatigue, nausea, weight loss, body aches) can be disabling. The disease can also behave like a silent killer, destroying a person’s liver over years without any symptoms. The Centers for Disease Control (CDC) recently issued a warning and recommends that everyone between the ages of 45 and 65 be tested -- potentially millions more could have the virus and not even know it. This story is about a cure for the disease -- a cure patients can’t get access to.

By Angela Covo, angela.covo@gmail.com

Last April, Bristol-Myers Squib (BMS) announced they achieved a 100 percent cure rate for HCV.

Using their HCV drug Daclatasvir together with an experimental drug from Gilead Sciences (GS) known as GS 7977 in phase 2 trials, the companies achieved a major milestone -- the 100 percent cure rate for HCV: type 1.They had similar results with the same drugs for HCV: type 2 and HCV: type 3, achieving a 91 percent cure rate.

The results of the all-oral combination are a huge advance, not only thanks to the remarkable results, but because they had mild side effects (think mild to moderate fatigue) that were well tolerated.

News of the cure moved the stock market and thrilled the medical world, which had been struggling with chemo-style therapies that were debilitating and not always effective.

In San Antonio, Margaret Dudley, who just missed entry to the successful study by a week, was overjoyed to learn a cure was found.

Almost exactly a year ago, Dudley went to see her doctor. She had been tired and just not feeling well for a couple of years and finally decided she needed a checkup. She learned she had HCV:type 3 and the treatment options were harsh with uncertain results. She has dropped more than 30 pounds since then – but she works hard not to let it hold her back.

And it’s a good thing Dudley is a fighter, because she decided to champion the millions of patients who won’t be getting the cure.

It turns out that BMS and GS have no plans to collaborate and move forward with phase 3 trials required to get the cure to market and the millions who desperately need the medication.

La Prensa contacted both companies by phone and by email. We asked both companies if they had plans to go forward with the phase 3 trials, but they would only comment they were trying to find the best options from all ongoing studies.

Cara Miller, spokesperson for Gilead Sciences, did not address the question and responded: “We are looking at the results from all of the ongoing studies to better understand what might be the best option or options for advancing as quickly as possible the best all-oral regimen.”

Bristol Myers-Squib at least acknowledged the existence of the phase II trials, but could not explain why the companies will not collaborate for the sake of the patients.

“We are committed to driving advances both through internal development and external collaborations to get the best treatment to patients. While this external collaboration was limited to Phase II, we have other external collaborations as well as many clinical trials involving our internally developed compounds, including a robust development program for our lead compound Daclatasvir, which continues to drive advances in the research and development of all oral combinations in HCV …,” Cristi Barnett, spokesperson for BMS, wrote in an email.

If the two companies do not collaborate, a new successful cocktail of drugs that works could take years – time many patients don’t have.

So Dudley, who likely picked up the virus at Permanent Cosmetics by John Shumate, explains she has “spent every waking moment since working on getting the word out.”

She founded the HCV Coalition for the Cure (hepc-cured.com) to lead the campaign to bring both companies to the table so they can move forward with their successful collaboration and get the cure for HCV to the market. Through the Coalition website, she manages a petition which has more than 7100 signatures.

“I hope people will be as outraged by this as we are and will take the time to visit the website and sign the petition. To think the cure everybody has been praying for is here, but not available because of corporate greed is shocking – why are they still chasing the cure when they’ve already found it?” Dudley said.

She also wants people to understand that HCV is not only spread by needles. It can happen when you share a razor, get a tattoo, permanent cosmetics or even a manicure when the utensils are not properly sanitized. Anybody can get HCV.

Just a few weeks ago, BMS halted another trial for an all-oral treatment for HCV using their Daclatasvir and a different drug because one patient died of heart failure and several others were hospitalized.

We contacted the Food and Drug Administration to ask if it was ethical to subject patients to potentially dangerous experimental treatments when an actual cure is available.

Stephenie Yao, a spokesperson for the FDA, responded, “We're not able to comment on this issue. Federal law prohibits our releasing information about any investigational new drug application.”

Dr. Robert Lanford of Texas Biomedical Research right here in San Antonio has been looking for the answer to HCV for 28 years.

“I’ve been working on the virus for 28 years – and we know we’re going to have a cure. There will be a whole series of cocktails because it may not be one size fits all,” he explained.

Still, Lanford agrees many patients can’t wait that long.

“It would be a good thing to allow 7977 and Daclatasvir to proceed to phase III at least temporarily … Gilead has a lot of good drugs to put into that cocktail but it’s still a question of time,” he said.

To learn more and to sign the petition, visit hepc-cured.com.

PHOTO: Founder of HCV Coalition for the Cure, Margaret Dudley accompanies her spouse, Gary Dudley, president and cofounder of SWBC, to the Alamo Colleges Open House earlier this week. Mrs. Dudley is working on getting out the news about a cure for HCV. Visit hepc-cured.com for more info. (Photo by Speedy Gonzalez)

Source

September 21, 2012

Despite Setbacks, Optimism on Drugs for Hepatitis C

Science 21 September 2012:
Vol. 337 no. 6101 pp. 1450-1451
DOI: 10.1126/science.337.6101.1450

News Focus

Infectious Disease

Jon Cohen

Summary

Bristol-Myers Squibb recently pulled the plug on a drug against hepatitis C virus, one of the furthest along in clinical trials of a new class of agents against HCV, because of toxicity. Researchers are now trying to understand why the drug failed and the impact it might have on other drugs in the pipeline—some of which work through similar mechanisms. Most are cautiously optimistic, however, that other drugs in development will pan out and that the failure will not seriously dent hopes of curing the disease with a short, relatively safe course of treatment that would work worldwide.

Read the Full Text (subscription required)

Source

New health education website launched

Thursday, 20 September 2012 21:41 AJPress

A NEW health education website, HepBsmart.com, sponsored by Gilead Sciences, Inc., intended for audiences in the United States, is launching Friday, September 7. HepBsmart.com contains practical information about chronic hepatitis B (CHB), a potentially life-threatening liver disease that affects an estimated two million people in the United States and is the leading cause of liver cancer.

Chronic hepatitis B is caused by a virus and can slowly damage the liver, without causing obvious symptoms. Chronic hepatitis B can be diagnosed with a simple blood test, prevented with a vaccine, and managed with appropriate care – but alarmingly, most people living with the disease don’t know they are infected.

Without treatment, 1 in 4 people with CHB may die of disease-related complications. The impact of chronic hepatitis B in the United States is more severe among Asian American communities.

HepBsmart.com features:

• Information on how to prevent CHB, testing for the disease, and management of CHB.

• An innovative animated video depicting a CHB patient’s journey from diagnosis to care (available in 14 languages with subtitles).

• Educational brochures in 14 languages, including Chinese, Korean, Vietnamese, and Tagalog among others.

HepBSmart.com is an educational website created by Gilead Sciences, a maker of medicines for chronic hepatitis B. The website is part of Gilead’s ongoing effort to raise community awareness of chronic hepatitis B.

Source

Idenix Pharma: Guilty By Association

By Nathan Sadeghi-Nejad 09/21/12 - 07:48 AM EDT

Stock quotes in this article: IDIX, BMY

NEW YORK (TheStreet) -- Thursday, Idenix Pharmaceuticals (IDIX) presented investors with a detailed update on IDX-184 and the earlier-stage IDX-19368, two hepatitis C drug candidates that were placed on clinical hold by the FDA last month.

Idenix' new investor slide deck, also filed as an SEC Form 8-K, offers lots of detail about the compounds' status and highlights management's admirably open-minded communication style. Unfortunately, I'm not convinced the company's woes will be easily fixed.

IDX-184 has had no safety issues to date. Nonetheless, structural similarities between Idenix's IDX-184 and Bristol-Myers Squibb's (BMY) BMS-094 were sufficient to warrant concern. Clinical development of the latter drug, which Bristol-Myers acquired in the $2.5 billion takeover of Inhibitex, has been discontinued because of severe cardiovascular toxicity.

The FDA's clinical hold -- effectively a "stop work" order triggered by unexpected safety issues -- suggests that regulators are also concerned about the safety of IDX-184. In order to get the clinical hold lifted and continue development, Idenix must now convince the FDA that IDX-184 doesn't put patients' lives at unnecessary risk. (At least one patient in the Bristol-Myers study died.)

Continue reading full article here …

Centre for Public Health report featured on BBC and ITV

21 September 2012

The outstanding research from LJMU’s Centre for Public Health has once again been recognised by the national media.

The report ‘Burden of Liver Disease and Inequalities in the North West of England’ published by the Centre and the Health Protection Agency North West in collaboration with the National Treatment Agency North West, North West Cancer Intelligence Service and NHS North West, presents data on liver disease and has received coverage on BBC and ITV, among others.

Liver disease currently accounts for 2% of all deaths in England, and its main causes are alcohol, hepatitis B and C, and fatty liver disease by age, gender, deprivation and geography.

The key findings from the report are that:

  • Numbers of men dying from liver disease each year in the North West are up 20% since 2005 (27 per 100,000 population in 2005 to 30.9 per 100,000 population in 2010), and deaths occur at a relatively young age (peak ages are 55 to 64 years). Numbers of deaths among women have remained fairly constant over time.
  • Deaths from liver disease are 42% higher in the North West compared to England (23.5 per 100,000 in North West, 16.6 per 100,000 in England, in 2010) and there are substantial variations within the region (42.7 per 100,000 population in Blackpool and 8.2 per 100,000 population in Eden in 2006 to 2010).
  • Hospital admissions for liver disease as the primary diagnosis increased 30% between 2005/6 and 2010/11 (from 6,413 to 8,334).
  • Alcohol-related liver disease1 accounts for 47% of liver disease deaths in men and 43% in women and affects more people living in deprived areas.
  • Hospital admissions due to fatty liver disease2 as a primary or secondary diagnosis have increased 182% (from 913 in 2005/6 to 2,578 in 2010/11).
  • Hepatocellular cancer3 accounts for 15% of male and 5% of female deaths from liver disease and chances of survival at five years for patients diagnosed with hepatocellular cancer are worse in the North West than in other areas of England (8.3% in the North West, 12.3% for England).
  • Laboratory reports of hepatitis C4 have increased 123% in the North West over the last decade (from 898 in 2000 to 2000 in 2010) and hospital admissions for hepatitis C as a primary or secondary diagnosis increased 65% since 2005 (from 2,929 in 2005 to 4,841 in 2010). 65% of injecting drug users tested positive for the hepatitis C virus in 2010.

Professor Martin Lombard, National Clinical Director for Liver Disease, commented: “Liver disease is emerging as one of the major health problems for our population. People can be at risk of developing liver disease from an early age and may not even know they have a liver problem until the disease is at an advanced stage. The main causes are alcohol, obesity and hepatitis viruses and there is a lot people can do to avoid liver disease or prevent its progression by looking after themselves, paying particular attention to their diet and reducing their habitual alcohol consumption. This report highlights the fact that in the North West liver disease has reached a very significant level, getting to the stage where most residents will know someone, or know someone who knows someone else, who has died of liver disease or has a health issue from liver disease. The report is a call to action to everyone interested in health and well being, to tackle this issue."

Professor Mark Bellis, Director of the Centre for Public Health, commented: “The increasing levels of obesity and alcohol consumption we have seen over recent decades have resulted in rising levels of liver disease across the North West, while much of Europe has seen levels fall. Liver disease is the tip of a growing iceberg of ill health resulting from poor diet and excessive drinking and a stark reminder that so far we have failed to tackle either.”

To see some of the coverage generated by the report, go to:

http://www.bbc.co.uk/news/uk-england-19632951

http://www.itv.com/news/granada/2012-09-18/new-report-reveals-rising-burden-of-liver-disease/

Source

The odds are too high to ignore

PUBLISHED: 19 Sep 2012 00:06:21 | UPDATED: 20 Sep 2012 00:45:58PUBLISHED: 19 Sep 2012

If 100 people are infected with hepatitis C, about 25 will clear the virus spontaneously and completely within six months of infection. They will still have antibodies in their blood and if exposed again can become re-infected.

The other 75 will develop a chronic infection and be at risk of cirrhosis of the liver. About 20 will experience no noticeable illness but will still be infectious and can transmit the virus to others.

About 15 years later, 40 to 60 of those with chronic infection will experience symptoms and develop some liver damage.

By 20 years, up to 10 of those with liver damage will develop cirrhosis. Of them, up to half will have liver failure or develop liver cancer.

The length of time from initial infection is a major determinant of the risk of cirrhosis and cancer.

Other determinants include alcohol intake, being male, being overweight and the age of infection. Beyond 40, the disease progresses faster. Hepatitis B and HIV are also factors.

Source

Race For Next Hepatitis C Drug Gets Tighter

untitled

A Bristol-Myers Squibb scientist conducts lab research. The company halted its phase-two study of a hepatitis C drug after a patient death.

By AMY REEVES, INVESTOR'S BUSINESS DAILY

Posted 09/18/2012 05:52 PM ET

The race for the next blockbuster hepatitis C drug is still at full speed, but the field is thinning out.

Last month, Bristol-Myers Squibb (BMY) officially pulled the plug on its candidate, BMS-986094, after it had to halt a phase-two study after the death of one of its subjects from heart failure. The Food and Drug Administration was so concerned about this development that it also put a hold on two similar drugs by Idenix (IDIX), punishing that biotech's already low-priced stock.

Bristol-Myers said it will take a $1.8 billion charge to end the study, which resulted not only in the one death but in the hospitalization of eight other people. "While the cause of these unexpected events, which involve heart and kidney toxicity, has not been definitively established, the company has determined that it is in the best interest of patients to halt development of BMS-986094," the company said.

Yet, the Centers for Disease Control at about the same time affirmed that the potential market for such a drug is huge. On Aug. 16, the CDC released new guidelines urging everyone born between 1945 and 1965 — baby boomers — should be tested for HCV, the hepatitis C virus. Previously it had only recommended testing for people who've injected illegal drugs or who received blood or organ donations before these things were properly screened. But the new report noted the "limited effectiveness" of this approach, and concluded that everyone from that generation notorious for its drug use and sexual activity is at sufficient risk for a test.

"With an HCV antibody prevalence of 3.25%, persons born during 1945—1965 account for approximately three-fourths of all chronic HCV infections among adults in the United States," the report said.

The CDC estimated that 2.7 million to 3.9 million Americans are living with HCV, though many don't realize it because the virus can germinate without causing symptoms for years. If left untreated, though, it can end up causing fatal liver damage.

Current treatment relies on pegylated interferon, which leaves much to be desired, so in the past year massive amounts of money have gone into creating better alternatives. Bristol's ill-fated drug came with its $2.5 billion buyout of Inhibitex in February, amid a rush by drugmakers to acquire hot HCV candidates. Not long before, Roche (RHHBY) shelled out $230 million for Anadys, and, in the most jaw-dropping development, Gilead Sciences (GILD) paid nearly $11 billion for Pharmasset.

Source

Fructose Intake Linked to Liver Damage

34864

By Michael Smith, North American Correspondent, MedPage Today

Published: September 20, 2012

Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner

In obese patients with diabetes, a high intake of fructose – a sugar widely used in soft drinks and other foods – is associated with impairment in cellular energy balance that may play a role in liver disease, researchers said.

A small pilot study also suggested that elevated uric acid levels in response to a fructose challenge might be a marker for energy depletion, according to Manal Abdelmalek, MD, of Duke University Medical Center, and colleagues.

The findings suggest that energy depletion in the liver might be a factor in the development and progression of nonalcoholic fatty liver disease (NAFLD), Abdelmalek and colleagues reported in the Sept. issue of Hepatology.

Increasing rates of NAFLD in the U.S. parallel those of type 2 diabetes and obesity, the researchers noted, while at the same time fructose consumption has more than doubled in the past 30 years.

The main player in that latter increase, Abdelmalek and colleagues wrote, is the use of high-fructose corn syrup -- a mixture of glucose and fructose -- to sweeten such foods as bread, cereal, and soft drinks.

"Given the concurrent rise in fructose consumption and metabolic diseases," Abdelmalek said in a statement, "we need to fully understand the impact of a high-fructose diet on liver function and liver disease."

Research has shown that in overweight or obese adults, fructose-sweetened beverages (but not their glucose-sweetened counterparts) increase lipogenesis, promote dyslipidemia, impair insulin sensitivity, and increase visceral fat.

There's also evidence linking fructose-sweetened beverages with the development of diabetes, so it's "plausible that habitual and/or excessive fructose consumption" might increase the risk of NAFLD and also exacerbate liver injury and promote fibrosis progression, the researchers wrote.

To investigate, they looked at the 244 participants in the Action for Health in Diabetes Fatty Liver Ancillary Study, where they have estimated dietary fructose consumption and measured both hepatic adenosine triphosphate (ATP) -- a compound involved in the energy transfer between cells -- and uric acid levels.

Abdelmalek and colleagues hypothesized that people with higher fructose intakes would have lower ATP, and that those with higher uric acid would be at higher risk for ATP depletion in the liver, following a fructose challenge.

To test those notions, they performed magnetic resonance spectroscopy and conducted a fructose challenge (with an intravenous bolus of the sugar) in a subset of 25 participants.

For the analysis, habitual fructose intake was classified as low or high -- below or above 15 g per day. The cutoff is about the same as Americans would have consumed -- mainly from fruits and vegetables -- before 1900, the researchers noted.

In addition, uric acid levels were deemed to be high if they were above 5.5 mg/dL of serum.

In the study subset, Abdelmalek and colleagues found that:

  • 64% had NAFLD, defined as more than 5% fat in the liver on magnetic resonance spectroscopy.
  • Average fructose consumption was 22.3 g per day in the high-intake group and 11.13 in the low-intake group, a significant difference (P<0.001).
  • Total energy intake averaged 1,716 calories a day in the high-fructose group and 1,497 in the low-fructose group (P=0.046).
  • Serum uric acid averaged 6.39 mg/dL in the high-uric acid group versus 4.35 in the low group (P<0.001).

The effect of the fructose challenge, they reported, was to lower hepatic ATP sharply before a rebound after 50 minutes.

Those with a habitually high fructose intake, they reported, began with lower hepatic ATP on average than those in the low-fructose group. They reached a lower nadir during the challenge, and their rebound was not as complete.

The pattern was similar for those with high uric acid levels, the researchers reported.

"High fructose consumption and elevated levels of uric acid are associated with more severe depletion of liver ATP," Abdelmalek said, adding that the findings suggest that increased dietary fructose intake impairs energy balance in the liver.

The researchers cautioned that the study was small, was not powered to determine significance, was cross-sectional without a control group, and had no randomized intervention.

Further research is needed, they added, to understand the role of uric acid and fructose in the development and progression of NAFLD.

The study was supported by the National Institute of Diabetes and Digestive and Kidney Disorders and the Johns Hopkins University School of Medicine General Clinical Research Center. The journal said Abdelmalek did not make any disclosures.

Primary source: Hepatology
Source reference:
Abdelmalek MK, et al "Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes" Hepatology 2012; 56: 952-960.

Source

Docs Don't Trust Pharma-Funded Studies

By Nancy Walsh, Staff Writer, MedPage Today

Published: September 20, 2012

Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner

Physicians tended to be skeptical of clinical trials funded by the pharmaceutical industry, even if they considered the study design to be methodologically rigorous, an analysis based on hypothetical studies found.

In a survey of board-certified internists, participants expressed more willingness to prescribe a drug evaluated in a highly rigorous hypothetical study (OR 3.07, 95% CI 2.18 to 4.32, P<0.001) than if the trial design was considered to have low methodologic rigor, according to Aaron S. Kesselheim, MD, JD, of Harvard Medical School in Boston, and colleagues.

Yet they were less likely to view a trial as having a rigorous design if industry funding was disclosed -- regardless of the methodologic quality of the study -- than if no funding source was provided (OR 0.63, 95% CI 0.46 to 0.87, P=0.006), the researchers reported in the Sept. 20 New England Journal of Medicine.

Prominent medical journals have made major efforts in recent years to provide conflict of interest information for published studies, but considerable skepticism remains on the part of clinicians regarding potential bias.

To explore the effects of funding disclosures on physicians' perceptions of study credibility, the researchers asked 263 physicians to examine a series of abstracts describing drug trials for three hypothetical newly approved drugs, and to rate their impressions of the studies and their willingness to accept the results.

For each of the three drugs, the researchers constructed an abstract that reflected a highly rigorous trial -- being randomized, double-blinded, having a large sample size and long follow-up, and providing safety data -- as well as abstracts that would be considered as reflecting medium- or low-level rigor.

All the abstracts reported that the results were statistically significant.

Each abstract then was amended to report no funding, industry funding, or support by the National Institutes of Health (NIH).

The median age of survey participants was 48, and more than two-thirds were men.

Participants reported having read a median of four journal abstracts within the previous month that related to prescription drugs.

When presented with simulated studies having low, medium, or high degrees of rigorous design, clinicians were likely to correctly identify high-quality trials (OR 3.95, 95% CI 2.81 to 5.55, P<0.001).

They also reported being more confident in the results of studies they considered highly rigorous (OR 2.73, 95% CI 1.95 to 3.82, P<0.001), and that they would be more willing to prescribe drugs evaluated in these trials.

But they reported having less confidence overall in studies sponsored by industry (OR 0.71, 95% CI 0.51 to 0.98, P=0.04), and being less likely to prescribe drugs from those studies (OR 0.68, 95% CI 0.49 to 0.94, P=0.02).

Participants also said they were less willing to consider industry-sponsored studies as being "important" than those sponsored by NIH (OR 0.59, 95% CI 0.42 to 0.82, P=0.002).

Physicians' unwillingness to prescribe drugs studied in industry-sponsored trials was greater regardless of whether the study design was high versus medium in rigor (P=0.87) or medium versus low rigor (P=0.83).

Conversely, they were more likely to prescribe a drug evaluated in a trial sponsored by NIH regardless of whether the study design was high versus medium rigor (P=0.81) or medium versus low rigor (P=0.56).

And regardless of sponsorship disclosure or the degree of methodologic rigor, physicians who felt strongly that drug company funding had an influence on trial results were less likely to prescribe a drug than were physicians who disagreed that funding played a role in study outcomes (OR 0.58, 95% CI 0.37 to 0.91, P=0.02).

The findings that the surveyed physicians held negative views of industry-sponsored clinical trials had "important implications," according to the researchers.

"Despite the occasional scientific and ethical lapses in trials funded by pharmaceutical companies, it is also true that the pharmaceutical industry has supported many major drug trials that have been of particular clinical importance," they observed.

The researchers commented that they found it "reassuring" that participants in their survey clearly were interested in the methodologic quality of the hypothetical studies.

However, they noted that if clinicians are overly skeptical about all industry-sponsored studies, major advances in drug treatment could be undervalued.

"Pharmaceutical companies seeking to enhance the appropriate use of important new products or to expand the appropriate uses of existing products must address the attitudes that our survey revealed, so that the credibility of the results of industry-supported trials is more likely to be based on methodologic rigor than on funding sources," Kesselheim and colleagues stated.

Among the strategies his group recommended were avoidance of "selective reporting" of trial results, ensuring the transparency of data, and allowing independent oversight of study endpoints.

In addition, because the physicians surveyed in this analysis rated NIH sponsorship highly, joint funding with industry might encourage trust in results.

"The methodologic rigor of a trial, not its funding disclosure, should be a primary determinant of its credibility," the researchers argued.

The study was supported by the Edmond J. Safra Center for Ethics at Harvard; the Agency for Healthcare Research and Quality; the Robert Wood Johnson Foundation; the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School; and the National Cancer Institute.

One author reported receiving grants from AstraZeneca and Novartis for data monitoring and trial analysis, and two others reported consulting for Merck and Genzyme/Sanofi.

Primary source: New England Journal of Medicine
Source reference:
Kesselheim A, et al "A randomized study of how physicians interpret research funding disclosures" N Engl J Med 2012; 367: 1119-1127.

Source

Stamp-Sized Device Could Cut Liver Test Costs

34874

By Michael Smith, North American Correspondent, MedPage Today

Published: September 20, 2012

Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner

A paper-based device about the size of a postage stamp could improve testing for drug-induced liver toxicity in the developing world, researchers reported.

In a series of experiments, the device agreed more than 90% of the time with the gold-standard tests for liver enzymes, according to Nira Pollock, MD, PhD, of Beth Israel Deaconess Medical Center in Boston, and colleagues.

At a projected cost of less than 10 cents a test, the device could make it significantly easier to monitor patients being treated for such diseases as TB and HIV in the developing world, where standard testing is difficult to obtain and costly, Pollock and colleagues reported in the Sept. 19 issue of Science Translational Medicine.

"Our device is designed to use a droplet of blood from a finger prick to deliver results in 15 minutes," Pollock said in a statement. "It could have significant implications around the world, particularly in developing nations where blood tests can be prohibitively expensive and the results can sometimes take weeks to return."

The device uses layers of patterned paper and a plasma separation membrane. Blood applied to the plasma separation membrane wicks into the layers of paper and travels through microfluidic channels to separate zones for testing aspartate aminotransferase (AST) and alanine aminotransferase (ALT).

The read-out is a series of dots that change color to report levels of the enzymes in three "bins" – less than 3 times the upper limit of normal (ULN), 3 to 5 times ULN, and more than 5 times ULN – that correspond to cut-offs used for clinical management of patients with TB and HIV, Pollock and colleagues reported.

The device was developed in collaboration with Diagnostics For All, a Cambridge, Mass., nonprofit organization.

The researchers tested the device on paired whole-blood and serum specimens, drawn simultaneously from 223 patients within the previous 5 hours for routine clinical testing and for which results of standard automated transaminase testing were available.

They applied 30 microliters of blood or serum to the devices and – after 15 minutes – three readers blinded to the gold-standard outcomes analyzed the results.

ALT results were more accurate for the serum samples than for whole blood, the researchers noted, possibly because of the age of the specimens at the time of analysis. Previous experiments had shown that values drifted higher as the whole blood aged.

But overall, Pollock and colleagues reported, the paper device got it right at least 90% of the time and was especially accurate in placing specimens in the lowest bins – those that would usually mean no action was needed.

For example, the paper device correctly placed 88 of 89 serum samples tested for ALT in the less than 3 times ULN bin and 85 of 88 tested for AST – accuracies of 99% and 97%, respectively.

No specimens that the standard test placed above 5 times ULN were misread by the paper device to be below 3 times ULN, Pollock and colleagues reported – an important finding given that guidelines for TB treatment suggest that patients with levels more than 5 times ULN stop their medications even in the absence of symptoms.

Pollock and colleagues cautioned that the device has still to be tested in the field with TB and HIV patients. A planned field trial in Ho Chi Minh City, Vietnam, will evaluate the performance of the test in 600 HIV patients from that city's Hospital of Tropical Diseases.

The study had support from the Department of Defense/Center for Integration of Medicine and Innovative Technology, the National Institutes of Health, and the Bill & Melinda Gates Foundation. A patent application has been filed based on the results; four authors are listed as inventors.

Primary source: Science Translational Medicine
Source reference:
Pollock NR, et al "A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing" Sci Transl Med 2012; DOI: 10.1126/scitranslmed.3003981.

Source

September 20, 2012

Sequestration Would Cut $538 Million From Domestic HIV/AIDS Programs

THE AIDS INSTITUTE LOGO

The AIDS Institute Urges Congress and the President to Find Agreement to Prevent Devastating Cuts

WASHINGTON, Sept. 19, 2012 /PRNewswire-USNewswire/ -- In a letter sent to Congressional leaders today, The AIDS Institute outlined $538 million in automatic spending cuts that would occur due to sequestration to four federal programs that people with HIV/AIDS depend upon for their lifesaving care and treatment, or which work to prevent future HIV infections. Unless Congress and the President come to an agreement on another option in the next couple of months, these cuts will automatically occur on January 2, 2013, because an agreement on how $1.2 trillion in budget cuts was not reached.

(Logo: http://photos.prnewswire.com/prnh/20110412/DC82138LOGO)

"With 50,000 new infections each year and a record 1.1 million people living with HIV/AIDS, with only 25 percent of them with a suppressed viral load, our Nation cannot afford to turn its back on addressing the domestic HIV/AIDS crisis," wrote leaders of The AIDS Institute. "It is imperative that alternatives to sequestration be identified and agreed upon by the Congress and the President so that these drastic cuts will not automatically occur."

The cuts of 8.2 percent represent just those that will occur in the first of nine years of planned cuts and are in addition to some previous year funding reductions. Based on a calculation using FY12 spending levels: 1) funding for HIV prevention at the CDC would be cut by $64 million; 2) the Ryan White HIV/AIDS Program, which provides care, treatment and support services to over half a million low income people with HIV/AIDS would be cut by $196 million, including $77 million from the AIDS Drug Assistance Program; 3) AIDS research at the NIH, which benefits both domestic and global AIDS, would be cut by $251 million; and 4) the Housing Opportunities for People with AIDS (HOPWA) program would be cut by $27 million. The total of these first year cuts would be $538 million.

The cut to ADAP could translate into approximately 9,400 patients losing access to their medications.

People with HIV/AIDS, many of whom are very poor, depend on other discretionary and non-discretionary programs in addition to those outlined above to keep them healthy that would also be impacted by sequestration.

In its letter, The AIDS Institute urged the Congress "to find a balanced solution to our Nation's fiscal situation. We understand there are serious budget concerns, but we also know that HIV/AIDS is an infectious disease that must be addressed by public health and our federal government must protect our Nation's most vulnerable, including people living with HIV/AIDS."

The AIDS Institute is a national nonprofit organization that promotes action for social change through public policy research, advocacy and education.

For more information and to become involved in AIDS advocacy work, please contact The AIDS Institute at: (202) 835-8373, or by email at: Info@theaidsinstitute.org or www.TheAIDSInstitute.org

Media Contact: Carl Schmid: (202) 669-8267  cschmid@theaidsinstitute.org

SOURCE The AIDS Institute

RELATED LINKS
www.TheAIDSInstitute.org

Source

A Modern 'Plague,' And The Heroes Who Tamed It

still-1-2-_wide-886c6eaa356a3e6125dcead6c2439bcd7380d82a-s4

William Lucas Walker/IFC Films

How to Survive a Plague features Peter Staley and others who fought to bring attention to the AIDS epidemic of the 1980s.

by Ella Taylor

September 20, 2012

Late in How to Survive a Plague, a fair-minded, careful history of the AIDS-activist movement ACT UP, comes an affecting montage that bears witness to the triumph and the tragedy of the New York-based group's radical crusade — a push to get affordable treatment for a disease that, at its peak in the late 1980s, was killing millions worldwide.

When asked, in the early 1990s, whether they expected to live themselves, not one of the founding members of ACT UP had said yes. Now middle-aged and older, several of those leaders — many of whom have been HIV-positive for 25 years — look healthy and a lot less angry than they did as young firebrands. They're happy to be alive, but they all break down in tears at the thought of the many colleagues who died before they could benefit from the combination drug therapy they'd fought so hard for.

Whether or not you were around in 1987, when ACT UP was born in the wake of a coruscating tirade by playwright Larry Kramer (The Normal Heart), the movie brings fresh news. Noting that the movement's birth coincided with the first camcorders, director David France, a longtime AIDS journalist, dug up a treasure trove of amateur videography chronicling the devastating passage of the disease among friends, family and lovers.

His film is neither circumspect nor obsessive with these difficult images, which France deftly integrates into an inspiring visual chronicle of ACT UP's flamboyant direct-action campaigns — all aimed at shaming government agencies, drug companies and the scientific community into taking swift action to find an affordable treatment.

Frustrated both by the inertia of industry and government health agencies on the one hand and the polite diplomacy of older AIDS organizations on the other, ACT UP leaders launched a barrage of theatrical, aggressive and sometimes strategically ill-mannered assaults on public figures.

It's hard to imagine a constituency better suited to putting on a show than New York's LGBT community. Or one with less to lose: Many of them were HIV-positive or had full-blown AIDS and could expect to die young, absent treatment that went beyond the ubiquitous quack remedies or the prohibitively expensive and hard-to-absorb drug AZT.

At 109 minutes, How to Survive a Plague is thorough almost to a fault. The film's villains get damning coverage — Ronald Reagan, New York mayor Ed Koch (who called ACT UP's actions "fascist") and then-President George H.W. Bush and New York archbishop John Cardinal O'Connor, both of whom tried to refocus public attention on promiscuity among some gay men. Meanwhile good eggs like Iris Long, a retired antiretroviral expert who wasn't gay but who counseled ACT UP on how to win reforms from the health agencies, get their due.

Long was among the few outsiders to chip in: Given public reaction to their rowdy methods, ACT UP mostly had to close ranks and rely on cheeky self-help. Refusing to succumb to the wagging fingers of clergy and politicians, members invaded St Patrick's Cathedral and renamed the cardinal "O' Condom." They ruined the president's golf game and wrapped Helms' house in a bright yellow condom. They held sit-ins in the offices of drug companies that overcharged for inadequate therapies; kiss-ins at hospitals where AIDS patients were mistreated or turned away; and "die-ins" at City Hall.

At a huge demonstration in Washington, D.C., they piggy-backed on the publicity generated by the AIDS Memorial Quilt by spilling the ashes of loved ones on the White House lawn. And when the police got rough, they chanted the mantra of the 1960s counterculture that had paved their way: "The whole world is watching."

Most important, the leaders of ACT UP — prominent among them Kramer, former bond trader Peter Staley, writer Mark Harrington and Bob Rafsky, a gifted orator with full-blown AIDS who famously lit into presidential candidate Bill Clinton — educated themselves as clinicians, bullied scientists into letting them in on research meetings and pushed to speed up clinical trials.

Still, research is time-consuming and tempers run short in those desperate times. France neither skirts nor overplays the internal rifts that all but short-circuited the movement's energies.

What saved the day was the stubborn persistence of its members, together with the scientific breakthroughs that led to protease inhibitors and combination therapies. Those new tools restored many near-corpses to life and cut the number of AIDS-related deaths in New York by a staggering 50 percent.

ACT UP soldiers on today, as it must, given the lack of official attention to the resurgence of HIV among young American men in metropolitan areas. The movement is quieter now, though, and by the standards of global street protests these days, its anarchic modus operandi back then may look pretty tame. But in the inward-looking 1980s, ACT UP was the best thing going in direct political action, and given the odds against the group, the magic it worked was remarkable. Occupy movements, take note.

Source

Better Hepatitis C Treatment Is Costly for Prisons

21TTPrison-popup

Michael Stravato for The Texas Tribune

Medications, bound for various prisons, on a conveyor belt at the Texas Department of Criminal Justice’s pharmacy.

The Texas Tribune
By BRANDI GRISSOM
Published: September 20, 2012

Tattooing is ubiquitous behind bars, despite — or perhaps because of — the fact that it is banned.

“It’s just unbelievable how creative they can be,” said Michele Deitch, a prisons expert at the University of Texas at Austin’s LBJ School of Public Affairs. “They can jerry-rig pens to become needles. They use the dyes in paper products.”

But the practice carries with it more than the risk of punishment — it can also spread hepatitis C.

The prison population is particularly prone to this viral disease, which is transmitted largely through infected blood and can lead to liver cirrhosis and cancer. Not only do inmates have a penchant for illicit tattoos, but they are also likelier than the general population to have engaged in high-risk behavior like intravenous drug use outside of prison. Prison health officials estimate that as many as 50,000 of the state’s more than 150,000 inmates could be infected with hepatitis C.

The cost to treat Texas inmates with hepatitis C is expected to soar by as much as 380 percent next year, a result of the growing prevalence of the disease among inmates and a more effective, but more expensive, treatment protocol. Legislators, already facing a strained budget, will have to find millions more dollars to pay for this care.

Not all inmates are tested for hepatitis C when they enter the prison system. They are tested if they have other clinical indicators, like H.I.V. or a history of intravenous drug use. In a 2007 report, health providers for the Texas Department of Criminal Justice said they had identified and were managing care for about 20,000 inmates with hepatitis C.

Dr. Stephanie Zepeda, the director of pharmacy services for University of Texas Medical Branch Correctional Managed Care, which oversees treatment of inmates, said she provided medication therapy for about 400 hepatitis C patients per month, at a cost to the state of about $2.8 million per year. Not all patients with the disease receive the medication, and the therapy can last from three months to a year.

The current protocol is composed of two drugs, and its cure rate is about 40 percent, Dr. Zepeda said. But new medical guidelines call for the use of a third medication, which can be one of two different drugs. One of them would increase the cost of hepatitis C treatment in prisons to more than $8 million a year, the other to more than $13 million, Dr. Zepeda said.

Dr. Zepeda said that adding a third drug raised the cure rate to 70 percent. But the drugs are not only expensive, they are also complicated to administer.

“It’s great from a humanistic standpoint,” Dr. Zepeda said. “But it’s, practically, a challenge for the correctional system.”

The new drugs must be administered precisely every eight hours. They must be taken with food, and patients risk developing a resistance to the therapy if they miss doses. In prison, where even small diversions from the regimented schedule require additional work for guards, and where inmates frequently move between units, ensuring that the expensive medications are given correctly could be problematic, Dr. Zepeda said.

“It just takes a tremendous amount of coordination to do it right and to do it well,” she said.

Another complicating factor, Dr. Zepeda said, is that new, potentially more effective drugs with simpler procedures are expected to be available as early as 2014.

In addition to these changes, the Centers for Disease Control and Prevention issued a new recommendation in August calling for all people born between 1945 and 1965 to be tested for hepatitis C. The C.D.C. estimates that this age group accounts for nearly three-quarters of all hepatitis C cases nationally.

More than a quarter of Texas prison inmates were born during that period, according to The Texas Tribune’s prisoner database. More testing, Dr. Zepeda said, is likely to result in diagnoses of more cases and an increased need for treatment.

For Texas lawmakers, this means high costs now and potentially exorbitant ones in the future as inmates age and the disease progresses, causing liver disease and failure. Additionally, failing to control the disease in prisoners presents serious health risks to the general population. Inmates who are not cured of hepatitis C and are released could spread the disease, which the C.D.C. reports is now the leading reason for liver transplants nationally.

“It is going to be a struggle as the disease continues to wreak havoc in the offender population,” said Dr. Owen Murray, the vice president of U.T.M.B.’s Correctional Managed Care program. (U.T.M.B. is a corporate sponsor of The Texas Tribune.)

Dr. Murray said policy makers should consider ways to control other costs in the prison health care system in order to mitigate the expense of treating hepatitis C. Perhaps, he said, offenders with expensive health needs whose crimes are less severe could be paroled earlier, or state agencies could work with pharmaceutical companies to secure lower rates for drugs. It would be ideal, he said, if the state teamed up with a nursing home to provide care to the growing population of elderly inmates.

Until then, Dr. Murray said, prison health officials will have to consider which patients immediately need hepatitis C treatment, and which ones can wait.

“Ultimately, it’s going to be much like H.I.V.,” Dr. Murray said. “You’re just going to have to acknowledge you have this disease in prison and that it costs a lot to treat.”

Ms. Deitch, the prisons expert, said preventing the use of dirty, homemade needles in prison by providing sterile ones for tattooing could be an inexpensive way to limit the spread of hepatitis C.

“Would you rather make those tools available or deal with the long-term cost consequences of the spread of the disease?” she asked.

Jason Clark, a spokesman for the criminal justice department, said the agency was not considering that, largely because of safety concerns. He said the agency already had rules in place to prevent the spread of diseases, including banning tattoos and sexual contact among inmates, along with the sharing of items like toothbrushes and razors.

In 1998, Mr. Clark said, the department began an education program focused on disease prevention. In the program, which is available in 99 of the state’s 111 prison facilities, 1,300 inmates teach other inmates about risk factors for infection and how to avoid them.

“They’re more likely to have firsthand knowledge about the risk factors among offenders, which gives them credibility,” Mr. Clark said.

State Senator John Whitmire, Democrat of Houston, dismissed the notion of allowing sterile needles in prisons. But he said lawmakers should consider solutions beyond financing medication for inmates.

“This is not just about inmates and their cellmates,” Mr. Whitmire said. “It’s about our communities where these inmates are being released.”

bgrissom@texastribune.org

Source

Analyte Health Launches New Campaign, Pricing to Encourage Hepatitis C Testing Among Baby Boomers

PR-Logo-Businesswire

PRESS RELEASE

Sept. 20, 2012, 11:00 a.m. EDT

CDC statistics indicate 1 in 30 people born between 1945 and 1965 have hepatitis C, which can lead to liver cancer; early detection can save lives

CHICAGO, Sep 20, 2012 (BUSINESS WIRE) -- Analyte Health, Inc., a privately held online medical services company offering specialty care, counseling and convenience not available in traditional primary care settings, announced today a new campaign to educate the public on high rates of hepatitis C among baby boomers. As part of that campaign, Analyte is offering reduced pricing to encourage more at-risk individuals to get tested through its two online clinics: Sexualhealth.com and STDTestExpress.com.

Hepatitis C is an infectious disease that primarily affects the liver. Individuals infected with hepatitis C often do not have symptoms, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis. In some cases cirrhosis can lead to liver failure, liver cancer or other life-threatening diseases. Data from the Centers for Disease Control (CDC) shows that people born between 1945 and 1965 are five times more likely to have the infection as people born earlier or later.

Analyte's hepatitis C testing campaign, starting first on Facebook, uses infographics to illustrate the sobering statistics, along with testing discounts intended to reach more individuals in the at-risk population. The campaign launches with a tab hosted on the company's Facebook page and 16 Facebook ads reaching 10 segments of the baby boomer population.

"Analyte's new campaign is a direct response to the CDC's initiative to improve screening for hepatitis C in the baby boomer population. Our goal is to get more people tested and improve lives," said Lisa Oldson, M.D., the medical director at Analyte Health.

The CDC reports that more than 15,000 Americans, the majority of which are baby boomers, die each year from hepatitis C and related illnesses, and estimates that testing and early treatment of hepatitis C could save more than 120,000 lives.

Anthony Priore, Analyte Health Chief Marketing Officer, noted that "with more than 4,000 diagnostic labs in our network and doctors licensed in all 50 states, we can offer easy, quick and convenient testing. Social media is our lead marketing channel because of its flexibility and broad reach, and we know that this particular population is very active there."

About Analyte Health, Inc.

Analyte Health is an innovative healthcare company based in Chicago, IL, that uses technology to help people gain greater access to expert medical care and information. Analyte Health delivers specialty care, counseling and convenience not available in a traditional primary care setting. Analyte Health offers individuals access via the web, mobile devices and telephone to a dedicated national team of doctors, nurses and health experts as well as more than 4,000 partner testing centers. Through more than 80,000 patient encounters to date, patients have trusted Analyte Health to deliver discreet and convenient STD testing and care. More information about the company is available at www.AnalyteHealth.com or on Facebook at https://www.facebook.com/SexHealthDotCom , Twitter at https://twitter.com/sexualhealth .

Forward-Looking Statements

Analyte Health, Inc. is a privately held company. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits to consumers from using Analyte Health's services. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of risks and uncertainties, including, among other things, the potential impact of regulatory and third party payer developments in the field of telehealth and STD testing, general business and economic conditions, changes in arrangements with vendors or suppliers, and costs or delays in obtaining or maintaining regulatory approvals and licenses. Any forward-looking statements in this release are based on limited information currently available to Analyte Health, which is subject to change, and Analyte Health will not necessarily update the information.

SOURCE: Analyte Health, Inc.

Source

Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study

Download the PDF here

Jnl of Hepatology Article In Press, corrected proof

"......it was notable that more cirrhotics had worse fatigue than those with minimal fibrosis....."

After treatment results

Once therapy terminated, the proportion of patients who admitted to feeling fatigued decreased. By 12weeks after discontinuation, the proportion of patients with fatigue was lower than that at baseline (36% in responders, 42% non-responders vs. 52% at baseline, Fig. 1A). The median fatigue VAS scores were also lower (11mm in responders, 17mm in non-responders vs. 25mm at baseline: Fig. 1B).

The improvement in fatigue was greater among patients who achieved an SVR than in those who never became HCV RNA negative (non-responders). Overall, the proportion of SVR patients who admitted to having fatigue decreased from 53% at baseline to 33%, 24weeks after treatment (p<0.0001; n=161), and the median VAS fatigue score decreased from 27mm to 13mm (p<0.0001; n=158). These changes were especially profound in patients who at baseline had severe levels of fatigue (fatigue VAS score >40mm), in whom the median fatigue VAS score decreased from 64mm at baseline to 21mm at follow-up week 24 (p<0.0001, n=66; Fig. 3A). Among non-responders, the presence and severity of fatigue decreased but not significantly between baseline and 24weeks after treatment regardless of the initial score (p>0.05, Fig. 3B). Furthermore, there was no significant change in fatigue presence or severity among patients who had virologic relapse (n=60) or breakthrough (n=21) (data not shown).

As expected, fatigue score was associated with depression, (Spearman correlation coefficients, rs=0.53 at baseline; 0.66 at treatment week 24; and 0.73 at follow-up week 24; all p<0.0001). Controlling for the presence of depression did not alter the significance of the changes in fatigue severity after successful completion of therapy compared to baseline (p<0.0001).

Fig 3. Severity of fatigue categorized by baseline fatigue status in responders and non-responders (NR). Severity of fatigue by baseline fatigue status in (A) responders and (B) NR patients.

Responders

Discussion

Fatigue is perhaps the most common symptom among patients with chronic hepatitis C and is a troublesome side effect of its therapy [1], [2], [4], [7], [9], [34], [35]. In this study, half of the patients enrolled in a study of antiviral therapy of HCV admitted that they had some degree of fatigue, of whom two-thirds rated it as moderate or severe. The current literature suggests that the presence and severity of fatigue correlate poorly with disease activity although it may be somewhat more common and severe in patients with cirrhosis [1], [9], [19], [36]. In the current study, the differences in frequency and severity of fatigue in patients with cirrhosis compared to those with lesser degrees of fibrosis were not statistically significant; however, the data were limited by numbers of patients with more advanced disease (n=29: 7% of the cohort) but it was notable that more cirrhotics had worse fatigue than those with minimal fibrosis.

As expected, fatigue became more troublesome during interferon therapy [9], [14], [15], [18]. Fatigue worsened during the first 4weeks of therapy, then plateaued, and did not completely resolve or return to baseline until 12weeks after stopping therapy. The cause of fatigue induced from interferon therapy is likely multifactorial, but may include the systemic effects of cytokines, secondary effects of treatment-related side effects such as anemia [37], [38], [39], [40], as well as the psychosocial stress of having to maintain occupational and family responsibilities while undergoing medical treatment. Thus, although attributing the cause of fatigue to a specific set of genes or proteins is an attractive and parsimonious notion, an interlinked pathway involving multiple genetic, biochemical, and environmental processes is a more realistic probability [41], and an area for future research.

Importantly, the presence and severity of fatigue ultimately declined in patients with sustained clearance of HCV. The results remained consistent even after controlling for depression, a common cofounder of fatigue. These findings indicate that therapy of HCV can result in significant and sustained improvement in clinical symptoms, and that the measurement of fatigue using VASs is successful in capturing these changes. Improvements in fatigue were most convincing in patients with moderate to severe levels of fatigue at baseline. Thus, patients with relatively non-significant biochemical or histologic disease, but who have troublesome symptoms such as fatigue, should be considered for antiviral therapy.

The likely cause for the improvement of fatigue with eradication of HCV is unclear. It is also unclear whether certain aspects of fatigue (i.e., physical, mental or cognitive) fare better, as the VAS is a quantitative measure rather than a qualitative one. While patient awareness of virological response could have a beneficial psychological effect on perceptions of fatigue, fatigue assessments were obtained before the results of virological testing were known, and improvements in fatigue were achieved well before knowledge of SVR was given to patients.

A few limitations of this study should be noted. The cohort tested was a relatively biased sample of patients with HCV infection, as these subjects all had genotype 1 and all were sufficiently motivated to undergo a rigorous, prolonged medical therapy with notable adverse side effects. Another caveat to consider is that the improvements in fatigue scores were observed predominantly among patients who had moderate or severe levels of fatigue before treatment, and there was little or no improvement in patients who initially reported minimal fatigue. Such findings suggest that there is little room for improvement in fatigue among those with lower levels at baseline, or that the VAS is not sensitive enough to detect minor improvements.

In conclusion, use of a simple fatigue VAS demonstrated that at least half of the patients with chronic hepatitis C who participated in a clinical trial had complaints of fatigue at baseline, however, fatigue significantly improved in those who achieved viral eradication. Further analyses of the quality of fatigue in chronic liver disease, as well as the biologic and psychosocial pathways associated with this subjective symptom are needed to improve management of chronic liver disease and assessment of the benefits of antiviral therapy, whether curative or ameliorative in nature.

Source

A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly

Published: September 20, 2012

STOCKHOLM, September 20, 2012 - /PRNewswire/ --
Medivir AB (OMX: MVIR), announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly developed by Medivir and Janssen Research & Development Ireland (Janssen). TMC647055 is a potent NNI (non-nucleoside inhibitor) of the HCV NS5B polymerase and is being developed by Janssen R&D.

"This study is in line with Medivir's and Janssen's strategy to evaluate different combination possibilities with simeprevir for interferon-free HCV treatments. This will broaden our understanding of simeprevir, which we believe has the necessary characteristics to potentially become a key component of future hepatitis C treatment regimens, including combination with interferon and ribavirin as well as interferon-free therapies," comments Charlotte Edenius, Medivir's EVP of Research and Development.

Study design

This will be an open label study in patients who are chronically infected with HCV genotype-1a or 1b to assess the efficacy, safety and tolerability of the combination. The primary endpoint in the study will be SVR12 (sustained virologic response 12 weeks after end of treatment). Simeprevir, TMC647055 and low-dose ritonavir will be co-administered once daily, with and without ribavirin.

Approximately 40 patients will be enrolled in this study, which is divided in two parts. The first part will include patients chronically infected with HCV genotype-1, who are either treatment-naive or have relapsed after prior pegylated interferon (PegIFN)/ribavirin treatment. The treatment will consist of simeprevir, TMC647055 and low-dose ritonavir, with and without ribavirin for 12 weeks.

The second part of the trial will investigate the same regimen in prior null responder patients chronically infected with HCV genotype 1a.

Recruiting: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Not yet recruiting: Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C

Completed: TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Medivir acquires preclinical antiviral programs including hepatitis C and prodrug technologies - press release

05-Sep-12 Stockholm, Sweden-

Medivir announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB.

The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir's hepatitis C platform and know how.

The acquired portfolio of research stage antiviral programs includes novel nucleotide polymerase inhibitors that have been identified and developed. It also includes prodrug technologies which could be applied to both protease inhibitors and nucleoside analogues to enhance their overall pharmacokinetic properties.

"We are very pleased to be able to make these additions to the Medivir R&D portfolio, which will further strengthen our pipeline and capabilities in the antiviral disease area. There are several synergies with the Medivir anti-viral projects and prodrug approaches which we aim to explore" comments Charlotte Edenius, Medivir's EVP of Research and Development .

The transaction value, which consists of up-front payment as well as future potential milestone payments, is not disclosed.

Source

September 17, 2012

Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness

September 17, 2012 | By John Carroll

Brian Starkey didn't have insurance coverage when he was diagnosed with hepatitis C. So when a doctor pointed him to a study of Bristol-Myers Squibb's ($BMY) experimental BMS-094, he leaped at a chance to get free care. And as The Kansas City Star reports in an in-depth profile, that decision may have cost him his life.

Starkey's sudden death after taking the treatment--along with severe heart ailments suffered by a big group of the 113 enrollees in the drug study--scuttled a program that inspired Bristol's $2.5 billion acquisition of Inhibitex. And the attorney representing Starkey's family tells the Midwestern newspaper that the risks of toxicity were already apparent when Bristol rushed into clinical studies, anxious to grab a lead in the frenzied race to develop a new hep C treatment that would not require interferon.

"This was a poorly designed study that caused serious injury," attorney Robert Hilliard told the Star. "I'm convinced that they rushed it into trials in order to get FDA approval." Hilliard's firm represents a half dozen of the injured patients, several with severe heart damage. One of the patients requires a heart transplant. All are suing Bristol.

BMS' response: "Based on our due diligence, we believed that we could develop BMS-986094 at a dose that would provide sufficient viral suppression and resistance coverage while also having an acceptable safety and tolerability profile." Bristol has also promised to help officials and other companies like Idenix ($IDIX) to get to the bottom of the drug reactions as quickly as possible.

The patient reactions in the 094 study have also forced Idenix to slam the brakes on two of its experimental programs as the FDA carefully considers whether patients are being exposed to unnecessary risks.

For Starkey's family, including his 19-month-old son, the exercise in caution came too late.

- here's the story from The Kansas City Star

Related Articles:
Deadly tox threat kills Bristol-Myers' $2.5B hep C prospect
Idenix plunges after FDA puts another hep C treatment on hold
Bristol mulls write-down of key hep C drug
Analyst reads last rites after heart failure scuttles Bristol hep C study

Source

Why 88% of US military veterans with HCV are not treated

Journal of Hepatology
Volume 57, Issue 4 , Page 924, October 2012

Bennet Cecil

Hepatitis C Treatment Centers, 1009A Dupont Square N, Louisville, KY 40207, USA

Received 21 March 2012; accepted 28 March 2012. published online 16 April 2012.

To the Editor:

The article in the February issue of the Journal of Hepatology reported that less than 12% of American military veterans identified with HCV were treated with antiviral therapy [1]. The Veterans Administration does not want to spend adequate funds to cure patients with hepatitis C. Dr. Kenneth Kizer, Under Secretary for Health in the US Department of Veterans Affairs (VA), gave HCV a high priority but unfortunately he left the VA in 1999. Subsequent leadership has not shown enthusiasm for treating HCV.

The Director of Pharmacy and the Chief of Staff at my local VA hospital told me that I spent too much money treating HCV. Boceprevir and telaprevir are both on the hospital formulary but telaprevir prescriptions are routinely denied because it is more expensive. Patients must jump multiple hurdles before qualifying for antiviral therapy. No one would refuse to give coronary artery stents or bypass grafts to a veteran who smokes but veterans who do not completely abstain from alcohol for three months are refused antiviral therapy. In spite of difficulties, 585 of 1372 (43%) HCV RNA positive patients received antiviral therapy between 1998 and 2010 at our local VA hospital; 226 of 583 treated (39%) achieved SVR [2]. 36% of deaths were from HCC or liver failure. Veterans with sustained viral response had substantially improved survival. Effective antiviral therapy improves prognosis [3], [4]. Less than 2% of Americans die from liver disease, but more than one third of veterans with HCV die prematurely from complications of cirrhosis [2], [5]. According to a 2010 national VA report, deaths in veterans with HCV have more than tripled, “Between 2000 and 2008, the annual number of all cause deaths recorded for Veterans with chronic HCV rose from 1259 (1129 per 100,000 in VHA care) to 5967 (4049 per 100,000 in VHA care), respectively” [6].

Legislation should be passed allowing veterans with HCV to prequalify for their choice of Medicaid or Medicare so that they can obtain antiviral therapy in the private sector. Since Dr. Kizer is no longer in charge of the VA, it is very clear that the VA is not going to treat very many of them.

Conflict of interest

Speakers Bureau Vertex Pharmaceuticals.

References

Source

Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients

logo-prn-01_PRN

Key Clinical Endpoints Met: JX-594 can be Safely and Efficiently Delivered Through Systemic Route, and Standard-of-Care Sorafenib Can Be Safely Administered Sequentially After JX-594, Opening Door to New Clinical Perspectives

BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC). The data were presented in an oral presentation at the International Liver Cancer Association (ILCA) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intra-tumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

The primary objective of this study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. The sequential treatment regimen was well tolerated with transient flu-like symptoms and transient leukopenia being the most common side effects related to JX-594. The sorafenib side effects observed were consistent with the expected toxicity profile of this product.

Secondary endpoints included the effect of the sequential treatment of JX-594 followed by sorafenib on disease control and tumor response. Evidence of antitumor activity was observed in both sorafenib-naive and sorafenib-refractory patients.

Importantly, this trial also demonstrated the feasibility of the systemic administration of the product (through intravenous injection).

"Our ability to deliver JX-594 intravenously to liver cancer tumors, further confirmed by these encouraging data, is a key attribute that sets it apart from other therapies in the class of oncolytic immunotherapies," stated David H. Kirn, M.D., founder, chief medical officer and president of R&D of Jennerex. "In the Phase 2 trial presented at ILCA, JX-594 demonstrated its ability to selectively target and destroy tumors following intravenous infusion. This finding confirms the ability of JX-594 to target both primary and metastatic, or distant, tumors which we believe is important in this HCC patient population and most cancers."

"We have treated more than 160 patients with JX-594 to date and are actively enrolling a multinational Phase 2b study in second line treatment of liver cancer patients, a Phase 2 all-IV trial in first line HCC patients, and a Phase 2 study in colorectal cancer. The data presented today build on the growing body of promising clinical data showing that JX-594 has a direct anti-tumor effect and can stimulate an immune response killing cancer cells," stated Laurent Fischer, M.D., president and chief executive officer of Jennerex. "We are excited with the progress we are making in our JX-594 program and believe it has the potential to advance patient care across multiple types of cancer."

The abstract (#2012-1304) entitled "Phase 2 Trial Of JX-594, A Targeted Multi-Mechanistic Oncolytic Vaccinia Virus, Followed By Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)" was presented at the International Liver Cancer Association Annual Meeting in Berlin.

About this Trial:

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intratumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

Following treatment with JX-594 alone at four weeks, 62 percent of patients had disease control as measured by modified RECIST (tumor burden measurement). Tumor biopsies of four patients following intravenous infusion showed four of four patients had local infection of JX-594 in tumor tissue while normal liver tissue was not affected, providing further evidence of JX-594's tumor selectivity and the ability to administer JX-594 intravenously. Furthermore, after six or 12 weeks, 59 percent of patients had disease control as measured by modified RECIST and 75 percent of patients had objective responses by Choi criteria. 85 percent of patients had disease control by mRECIST and /or Choi response.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer
JX-594 is a proprietary, engineered oncolytic immunotherapy designed to selectively target and destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells 2) the stimulation of an immune response against cancer cells, (i.e., active immunotherapy), and 3) the shutdown of the blood supply to tumors. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated (over 160 patients treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable, predictable and generally mild safety profile to date which includes flu-like symptoms that resolve in 24 to 48 hours.

JX-594 takes advantage of the natural attributes of poxviruses and was engineered to target and destroy solid tumors both systemically and locally. The vaccinia virus backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic abnormalities in cancer cells. JX-594 was engineered to enhance this cancer-selectivity by inactivating its thymidine kinase (TK) gene and encode the immunogenic GM-CSF gene, to enhance the immune response against cancer cells.

Hepatocellular Carcinoma: A Global Unmet Need
Hepatocellular carcinoma is the fifth most common cancer worldwide and the third leading cause of cancer death, with over 600,000 new cases diagnosed annually resulting in more than 90 percent mortality. The annual incidence rate in the U.S., Europe, Japan and China are estimated to be 20,000, 55,000, 40,000 and 350,000 patients, respectively. The only treatment approved for HCC is sorafenib. There is no treatment approved for patients who fail sorafenib.

About Jennerex's Partners for JX-594
Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX-594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1/2 clinical trials in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common solid tumor types and trigger a potent immune response. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through targeted viral replication, the ablation of the blood supply to tumors and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com. For studies evaluating JX-594 please visit www.clinicaltrials.gov.

SOURCE Jennerex, Inc.

RELATED LINKS
http://www.jennerex.com

Source